摘要
目的比较格列齐特与格列本脲对2型糖尿病患者的疗效与安全性。方法在线检索中国知网、万方数据库、维普数据库、Cochrane图书馆、PubMed、MEDLINE、Embase等中外医学数据库,纳入格列齐特与格列本脲治疗2型糖尿病的随机对照试验或系统评价,检索日期截止到2013年6月31日。按照Cochrane系统评价方法,评价纳入研究的文献质量,并运用RevMan 5.0软件进行Meta分析。结果共纳入16篇文献,其中英文8篇,中文8篇。Meta分析结果显示,试验组(格列齐特组,包括格列齐特普通片与格列齐特缓释片)与对照组(格列本脲普通片组)相比,两组2型糖尿病患者各项治疗指标(2 hPG、HbA_(1C))比较组间差异无统计学意义,但格列齐特组低血糖发生率明显低于格列本脲组。结论格列齐特与格列本脲对2型糖尿病患者的疗效相似,但格列齐特安全性更好。
Objective To compare the efficacy and safety of gliclazide and glyburide in type 2 diabetic patients. Methods All literature published before June 31^（th）, 2013, which was related to randomized controlled trials（RCTs） or system evaluation of glyburide vs glibenclamide in the treatment of type 2 diabetic patients, was collected comprehensively from CNKI, Wan Fang database, VIP, Cochrane Library, PubMed, MEDLINE, Embase, and other medical databases. The quality of collected literature was evaluated through the method of Cochrane system evaluation, the Meta-analysis was conducted by using Rev Man 5.0 software. Results A total of 16 articles were included, of which 8 were in English and others were in Chinese. As showed by the Meta-analysis, there were no significant difference of the efficacy in type 2 diabetic patients between the experimental group（gliclazide group, including gliclazide tablets and gliclazide MR） and the control group（glyburide tablets group）, but the low blood sugar side effect of experimental group was significantly lower than that of control group. Conclusion Gliclazide and glyburide have a similar effect on type 2 diabetic patients, but gliclazide is better on safety compared with glyburide.
出处
《世界临床药物》
CAS
2015年第12期832-837,845,共7页
World Clinical Drug
基金
"十二五"国家科技支撑计划课题"安全合理用药评价和干预技术研究与应用"(编号:2013BAI06B04)
